Kezar Life Sciences, Inc. Financials

KZR

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 9 available years

Income Statement	DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021
Revenues
Revenue	$0	$0	$7	$0	$0
General & Administrative	$19	$23	$27	$20	$16
Research & Development	$34	$66	$86	$51	$39
Total Operating Expenses	$59	$91	$118	$71	$55
Operating Income	-$59	-$91	-$111	-$71	-$55
Non-Operating
Net Interest Expense	$4	$7	$10	$3	-$0
Other Non-Operating Income (Expense)	-$1	$0	$0	–	–
EBT (Earnings Before Tax)	-$56	-$84	-$102	–	–
Income Tax Expense	$0	$0	$0	$0	$0
Net Income
Net Income	-$56	-$84	-$102	-$68	-$55
Per Share Data
Revenue Per Share	$0.00	$0.00	$0.10	$0.00	$0.00
EPS (Basic)	-$7.66	-$11.49	-$14.04	-$10.13	-$1.04
EPS (Diluted)	-$7.66	-$11.49	-$14.04	-$10.13	-$1.04
Weighted Avg Shares (Basic)	7.3M	7.3M	72.6M	67.4M	52.8M
Weighted Avg Shares (Diluted)	7.3M	7.3M	72.6M	67.4M	52.8M
Shares Outstanding	7.3M	7.3M	72.6M	67.4M	52.8M
Dividends Per Share	$0.00	$0.00	$0.00	$0.00	$0.00

Kezar Life Sciences (KZR) financials: revenue, profit and margins

Kezar Life Sciences (KZR) generated about n/a in revenue and -$45 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Kezar Life Sciences profitable?+

Kezar Life Sciences reported about -$45 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on KZR: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 6 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with KZR

CompareIntrinsic value

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

HCWBHCW Biologics Inc.

$1.08-6.09%15

ALMSAlumis Inc.

$6.55+0.77%10

ROIVRoivant Sciences Ltd

$38.23+6.08%16

ADAGAdagene Inc.

$2.41+2.55%25

COYACoya Therapeutics Inc.

$3.08-0.96%10

ABEOAbeona Therapeutics Inc.

$4.22-0.71%40

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

Spot a number that looks wrong? Check it in KZR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KZR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.